A detailed history of Black Rock Inc. transactions in Dare Bioscience, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 203,632 shares of DARE stock, worth $647,549. This represents 0.0% of its overall portfolio holdings.

Number of Shares
203,632
Previous 396,098 48.59%
Holding current value
$647,549
Previous $194,000 64.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.28 - $0.61 $53,890 - $117,404
-192,466 Reduced 48.59%
203,632 $69,000
Q1 2024

May 10, 2024

SELL
$0.31 - $0.57 $2,029 - $3,731
-6,547 Reduced 1.63%
396,098 $194,000
Q4 2023

Feb 13, 2024

SELL
$0.29 - $0.53 $684 - $1,250
-2,360 Reduced 0.58%
402,645 $124,000
Q3 2023

Nov 13, 2023

SELL
$0.46 - $0.91 $5,086 - $10,061
-11,057 Reduced 2.66%
405,005 $186,000
Q2 2023

Aug 11, 2023

SELL
$0.91 - $1.05 $191,542 - $221,010
-210,486 Reduced 33.59%
416,062 $378,000
Q1 2023

May 12, 2023

SELL
$0.87 - $1.36 $78,258 - $122,334
-89,952 Reduced 12.55%
626,548 $651,000
Q4 2022

Feb 13, 2023

BUY
$0.82 - $12.6 $6,578 - $101,077
8,022 Added 1.13%
716,500 $594,000
Q3 2022

Nov 14, 2022

SELL
$1.04 - $12.48 $5,731 - $68,777
-5,511 Reduced 0.77%
708,478 $709,000
Q2 2022

Aug 12, 2022

BUY
$0.94 - $1.76 $105,235 - $197,037
111,953 Added 18.6%
713,989 $878,000
Q1 2022

May 12, 2022

BUY
$1.42 - $2.09 $332,625 - $489,567
234,243 Added 63.69%
602,036 $897,000
Q4 2021

Feb 10, 2022

BUY
$1.42 - $2.13 $347,996 - $521,994
245,068 Added 199.69%
367,793 $735,000
Q3 2021

Nov 09, 2021

SELL
$1.42 - $2.0 $17,287 - $24,348
-12,174 Reduced 9.02%
122,725 $205,000
Q2 2021

Aug 11, 2021

BUY
$1.21 - $1.89 $163,227 - $254,959
134,899 New
134,899 $255,000

Others Institutions Holding DARE

About Dare Bioscience, Inc.


  • Ticker DARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,820,896
  • Market Cap $270M
  • Description
  • Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription pr...
More about DARE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.